Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica aguda

Background: The low notification of Adverse Drug Reactions (ADR) underscores the need for pharmacological surveillance systems that allow their detection, evaluation, prevention and registry especially in patients receiving multiple medications. Aim: To communicate the ADR observed with the use E co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kyonen L,Mónica, Folatre B,Isabel, Zolezzi R,Paolina, Badilla M,Viviana, Marín H,Francisco
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2006
Materias:	Asparaginase Drug toxicity Leukemia, lymphocytic
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006001200006
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872006001200006
record_format	dspace
spelling	oai:scielo:S0034-988720060012000062007-01-24Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica agudaKyonen L,MónicaFolatre B,IsabelZolezzi R,PaolinaBadilla M,VivianaMarín H,Francisco Asparaginase Drug toxicity Leukemia, lymphocytic Background: The low notification of Adverse Drug Reactions (ADR) underscores the need for pharmacological surveillance systems that allow their detection, evaluation, prevention and registry especially in patients receiving multiple medications. Aim: To communicate the ADR observed with the use E coli asparaginase (E coli ASP) in children with Acute Lymphatic Leukemia (ALL). Patients and Methods: Cross-sectional study of clinical records of all the patients aged less than 15 years with ALL (n =52) and treated between January 1996 and April 2000. The suspicion of ADR to E coli ASP was evaluated using the Karch and Lasagna algorithm. Probable and definitive cases of ADR to E coli ASP were subjected to a protocol of clinical and epidemiological data. The risk factors associated to ADR to E coli ASP, were also determined. Results: Fifty children aged 1 to 13 years (33 men) were studied. In 20 (40%), an ADR to E coli ASP, was suspected. After the use of the algorithm, the ADR was considered definite in two patients, probable in 17 and possible in one. The registered clinical events were urticaria in 17, anaphylactic shock in four, transient alterations of hepatic functions test in seven and hypofibrinogenemia in four. The test of cutaneous sensitivity to the administration of E coli ASP, performed prior to the administration of the drug, were positive in nine of the 20 children with adverse reactions. No children died. Conclusions: The application of the Karch anbd Lasagna algorithm, allowed us to objectively classify suspected cases of ADR by E coli ASPinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.134 n.12 20062006-12-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006001200006es10.4067/S0034-98872006001200006
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Asparaginase Drug toxicity Leukemia, lymphocytic
spellingShingle	Asparaginase Drug toxicity Leukemia, lymphocytic Kyonen L,Mónica Folatre B,Isabel Zolezzi R,Paolina Badilla M,Viviana Marín H,Francisco Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica aguda
description	Background: The low notification of Adverse Drug Reactions (ADR) underscores the need for pharmacological surveillance systems that allow their detection, evaluation, prevention and registry especially in patients receiving multiple medications. Aim: To communicate the ADR observed with the use E coli asparaginase (E coli ASP) in children with Acute Lymphatic Leukemia (ALL). Patients and Methods: Cross-sectional study of clinical records of all the patients aged less than 15 years with ALL (n =52) and treated between January 1996 and April 2000. The suspicion of ADR to E coli ASP was evaluated using the Karch and Lasagna algorithm. Probable and definitive cases of ADR to E coli ASP were subjected to a protocol of clinical and epidemiological data. The risk factors associated to ADR to E coli ASP, were also determined. Results: Fifty children aged 1 to 13 years (33 men) were studied. In 20 (40%), an ADR to E coli ASP, was suspected. After the use of the algorithm, the ADR was considered definite in two patients, probable in 17 and possible in one. The registered clinical events were urticaria in 17, anaphylactic shock in four, transient alterations of hepatic functions test in seven and hypofibrinogenemia in four. The test of cutaneous sensitivity to the administration of E coli ASP, performed prior to the administration of the drug, were positive in nine of the 20 children with adverse reactions. No children died. Conclusions: The application of the Karch anbd Lasagna algorithm, allowed us to objectively classify suspected cases of ADR by E coli ASP
author	Kyonen L,Mónica Folatre B,Isabel Zolezzi R,Paolina Badilla M,Viviana Marín H,Francisco
author_facet	Kyonen L,Mónica Folatre B,Isabel Zolezzi R,Paolina Badilla M,Viviana Marín H,Francisco
author_sort	Kyonen L,Mónica
title	Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica aguda
title_short	Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica aguda
title_full	Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica aguda
title_fullStr	Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica aguda
title_full_unstemmed	Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica aguda
title_sort	reacciones adversas a l-asparaginasa en pacientes con leucemia linfoblástica aguda
publisher	Sociedad Médica de Santiago
publishDate	2006
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006001200006
work_keys_str_mv	AT kyonenlmonica reaccionesadversasalasparaginasaenpacientesconleucemialinfoblasticaaguda AT folatrebisabel reaccionesadversasalasparaginasaenpacientesconleucemialinfoblasticaaguda AT zolezzirpaolina reaccionesadversasalasparaginasaenpacientesconleucemialinfoblasticaaguda AT badillamviviana reaccionesadversasalasparaginasaenpacientesconleucemialinfoblasticaaguda AT marinhfrancisco reaccionesadversasalasparaginasaenpacientesconleucemialinfoblasticaaguda
_version_	1718436297277702144

Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica aguda

Ejemplares similares